A fixed-dose combination (FDC) of three distinct pharmacological agents designed for comprehensive secondary prevention of atherothrombotic events, particularly in patients with established cardiovascular disease (CVD) or post-acute coronary syndrome (ACS). Aspirin and Clopidogrel provide synergistic antiplatelet action via different pathways (dual antiplatelet therapy - DAPT), while Atorvastatin provides intensive lipid-lowering and plaque-stabilizing effects. This combination is a cornerstone of secondary prevention strategies in India, aiming to improve adherence and reduce the risk of recurrent myocardial infarction (MI), stroke, and cardiovascular death.
Adult: One tablet (Aspirin 75mg + Atorvastatin 20mg + Clopidogrel 75mg) orally once daily. For post-ACS/PCI, a Clopidogrel loading dose (300mg or 600mg) may be given separately before initiating this FDC. Atorvastatin dose may be uptitrated to 40mg or 80mg based on lipid goals and tolerance, requiring separate prescriptions.
Note: Administer once daily, with or without food. Evening administration may be preferred for Atorvastatin due to theoretical circadian rhythm of cholesterol synthesis, but clinical significance is minimal. Tablet should be swallowed whole with a glass of water. Do not crush or chew. If a dose is missed, take it as soon as remembered. If it is near the time for the next dose, skip the missed dose. Do not double the dose.
This combination exerts a triple-action mechanism: 1) Anti-inflammatory & Antiplatelet (Aspirin): Irreversibly acetylates platelet cyclooxygenase-1 (COX-1), inhibiting thromboxane A2 (TXA2) synthesis, a potent platelet aggregator and vasoconstrictor. 2) Lipid Modification & Plaque Stabilization (Atorvastatin): Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis, leading to upregulation of LDL receptors and increased clearance of LDL-C from blood. It also has pleiotropic effects (improved endothelial function, anti-inflammatory, plaque stabilization). 3) Alternative Antiplatelet Pathway Inhibition (Clopidogrel): Irreversibly inhibits the P2Y12 subtype of ADP receptor on platelet surface, preventing ADP-mediated activation of the GPIIb/IIIa complex and subsequent platelet aggregation. The dual antiplatelet action (Aspirin + Clopidogrel) provides synergistic inhibition of platelet aggregation.
Pregnancy: CATEGORY D (Aspirin/Clopidogrel) and CATEGORY X (Atorvastatin). Contraindicated. Aspirin in third trimester can cause premature closure of ductus arteriosus, increased maternal and neonatal bleeding. Statins are teratogenic. Discontinue immediately if pregnancy is detected.
Driving: Usually no effect. However, dizziness, vertigo, or visual disturbances reported rarely. Caution patients if they experience such symptoms.
| Warfarin / DOACs (Apixaban, Rivaroxaban, Dabigatran) | Profoundly increased risk of major and fatal bleeding. | Contraindicated / High |
| NSAIDs (Ibuprofen, Diclofenac, Naproxen) | Increased GI bleeding risk, may antagonize Aspirin's antiplatelet effect. | High |
| Proton Pump Inhibitors (Omeprazole, Esomeprazole) | Omeprazole/Esomeprazole are CYP2C19 inhibitors, may reduce Clopidogrel's efficacy. Pantoprazole is preferred. | Moderate |
| Strong CYP3A4 Inhibitors (Itraconazole, Ketoconazole, Clarithromycin, HIV protease inhibitors) | Increase Atorvastatin levels, high risk of myopathy/rhabdomyolysis. | High |
| Other Antiplatelets (Ticagrelor, Prasugrel) | Excessive antiplatelet effect, severe bleeding risk. | Contraindicated / High |
| SSRIs (Fluoxetine, Sertraline) | Increased bleeding risk due to impaired platelet serotonin uptake. | Moderate |
| Corticosteroids (Prednisolone) | Increased GI ulceration and bleeding risk. | Moderate |
| Grapefruit Juice | Inhibits CYP3A4, can increase Atorvastatin levels and risk of myopathy. | Moderate |
Same composition (Aspirin (75mg) + Atorvastatin (20mg) + Clopidogrel (75mg)), different brands: